Durian. The United Kingdom has agreed to purchase 100 million doses of covid-19 vaccine that hopefully will be manufactured in the near future following a positive result from collaboration research between Oxford University and the UK-based global biopharmaceutical firm AstraZeneca on candidate vaccine, the country’s representative office in Indonesia said on July 20.
The University of Oxford in its statement on July 20 said there are supply commitment have been made by the UK, the United States, European countries and other for at least 2 billion doses of covid-19 vaccine.
The latest phase of vaccine trial to more than 1,000 healthy volunteers, aged between 18 to 55 years, through a randomized control method, showed “there were no serious adverse health events related to ChAdOx1 nCov-19”, according to Oxford.
Those 1,077 volunteers were given the vaccine between April 23 to May 21, 2020 and clinical tests resulted 90 percent of the vaccine recipients could produce antibody towards covid-19 virus, the UK embassy in Jakarta said in its statement that was sent to thebigdurian.news.
Therefore, another phase of clinical trial should be taken for global respondents which are expected for 30,000 volunteers in the US despite ongoing trials in Brazil and South Africa. The trial for the US’ respondents will be a pediatric study, the university said.
The UK government funds the vaccine project with £84 million ($106.3 million) for the acceleration of the vaccine’s development.
“Today’s results are extremely encouraging, taking us one step closer to finding a successful vaccine to protect millions in the UK and across the world,” Business Secretary Alok Sharma said.
“The agility and speed with which the University of Oxford have been working is outstanding. I am very proud of what they have achieved so far,” Sharma added.
